-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Pharvaris (NASDAQ:PHVS) Price Target Lowered to $20.00 at SVB Leerink
Pharvaris (NASDAQ:PHVS) Price Target Lowered to $20.00 at SVB Leerink
Pharvaris (NASDAQ:PHVS – Get Rating) had its target price reduced by SVB Leerink from $25.00 to $20.00 in a report published on Wednesday, The Fly reports. SVB Leerink currently has an outperform rating on the stock.
Several other research analysts have also commented on PHVS. JMP Securities dropped their price target on shares of Pharvaris from $34.00 to $18.00 and set a mkt outperform rating on the stock in a research note on Tuesday. Morgan Stanley lowered shares of Pharvaris from an overweight rating to an equal weight rating and dropped their price target for the stock from $40.00 to $10.00 in a research note on Tuesday, August 23rd. Oppenheimer dropped their price target on shares of Pharvaris from $48.00 to $22.00 and set an outperform rating on the stock in a research note on Tuesday, August 23rd. Finally, Bank of America lowered shares of Pharvaris from a neutral rating to an underperform rating and dropped their price target for the stock from $26.00 to $13.00 in a research note on Monday, August 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, Pharvaris has a consensus rating of Hold and an average price target of $16.60.
Get Pharvaris alerts:Pharvaris Trading Up 0.8 %
Shares of NASDAQ PHVS opened at $9.14 on Wednesday. The firm has a market capitalization of $291.06 million, a PE ratio of -3.52 and a beta of -0.19. The business has a 50-day moving average price of $16.74 and a two-hundred day moving average price of $17.99. Pharvaris has a one year low of $8.55 and a one year high of $27.50.
Pharvaris (NASDAQ:PHVS – Get Rating) last issued its quarterly earnings data on Monday, September 12th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.19. Research analysts anticipate that Pharvaris will post -2.18 EPS for the current year.Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE grew its position in Pharvaris by 1,054.4% in the 1st quarter. Bank of America Corp DE now owns 5,772 shares of the company's stock worth $105,000 after purchasing an additional 5,272 shares during the last quarter. DAFNA Capital Management LLC grew its position in Pharvaris by 4.7% in the 4th quarter. DAFNA Capital Management LLC now owns 36,720 shares of the company's stock worth $528,000 after purchasing an additional 1,646 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Pharvaris by 2.0% in the 2nd quarter. Goldman Sachs Group Inc. now owns 56,951 shares of the company's stock worth $1,259,000 after purchasing an additional 1,115 shares during the last quarter. Eventide Asset Management LLC grew its position in Pharvaris by 23.6% in the 1st quarter. Eventide Asset Management LLC now owns 302,619 shares of the company's stock worth $5,659,000 after purchasing an additional 57,694 shares during the last quarter. Finally, Novo Holdings A S grew its position in Pharvaris by 23.2% in the 4th quarter. Novo Holdings A S now owns 516,321 shares of the company's stock worth $7,430,000 after purchasing an additional 97,378 shares during the last quarter. 70.21% of the stock is currently owned by institutional investors and hedge funds.
Pharvaris Company Profile
(Get Rating)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).
Read More
- Get a free copy of the StockNews.com research report on Pharvaris (PHVS)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
Pharvaris (NASDAQ:PHVS – Get Rating) had its target price reduced by SVB Leerink from $25.00 to $20.00 in a report published on Wednesday, The Fly reports. SVB Leerink currently has an outperform rating on the stock.
據The Fly報道,在週三發佈的一份報告中,SVB Leerink將Pharvaris(納斯達克:PHVS-GET Rating)的目標價從25.00美元下調至20.00美元。SVB Leerink目前對該股的評級為跑贏大盤。
Several other research analysts have also commented on PHVS. JMP Securities dropped their price target on shares of Pharvaris from $34.00 to $18.00 and set a mkt outperform rating on the stock in a research note on Tuesday. Morgan Stanley lowered shares of Pharvaris from an overweight rating to an equal weight rating and dropped their price target for the stock from $40.00 to $10.00 in a research note on Tuesday, August 23rd. Oppenheimer dropped their price target on shares of Pharvaris from $48.00 to $22.00 and set an outperform rating on the stock in a research note on Tuesday, August 23rd. Finally, Bank of America lowered shares of Pharvaris from a neutral rating to an underperform rating and dropped their price target for the stock from $26.00 to $13.00 in a research note on Monday, August 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, Pharvaris has a consensus rating of Hold and an average price target of $16.60.
其他幾位研究分析師也對PHV發表了評論。JMP Securities週二在一份研究報告中將Pharvaris的目標價從34.00美元下調至18.00美元,並對該股設定了Mkt的表現優於大盤的評級。在8月23日星期二的一份研究報告中,摩根士丹利將Pharvaris的股票評級從增持下調至持平評級,並將該股的目標價從40美元下調至10美元。奧本海默在8月23日(星期二)的一份研究報告中將Pharvaris的股票目標價從48.00美元下調至22.00美元,並對該股設定了強於大盤的評級。最後,在8月22日星期一的一份研究報告中,美國銀行將Pharvaris的股票評級從中性下調至表現不佳,並將其股票目標價從26.00美元下調至13.00美元。一名分析師對該股的評級為賣出,一名分析師給出了持有評級,兩名分析師給出了該公司的買入評級。根據MarketBeat的數據,Pharvaris的共識評級為持有,平均目標價為16.60美元。
Pharvaris Trading Up 0.8 %
Pharvaris股價上漲0.8%
Shares of NASDAQ PHVS opened at $9.14 on Wednesday. The firm has a market capitalization of $291.06 million, a PE ratio of -3.52 and a beta of -0.19. The business has a 50-day moving average price of $16.74 and a two-hundred day moving average price of $17.99. Pharvaris has a one year low of $8.55 and a one year high of $27.50.
週三,納斯達克PHV的股價開盤報9.14美元。該公司市值為2.9106億美元,市盈率為-3.52,貝塔係數為-0.19。該業務的50日移動均線價格為16.74美元,200日移動均線價格為17.99美元。Pharvaris的一年低點為8.55美元,一年高位為27.50美元。
Institutional Inflows and Outflows
機構資金流入和流出
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE grew its position in Pharvaris by 1,054.4% in the 1st quarter. Bank of America Corp DE now owns 5,772 shares of the company's stock worth $105,000 after purchasing an additional 5,272 shares during the last quarter. DAFNA Capital Management LLC grew its position in Pharvaris by 4.7% in the 4th quarter. DAFNA Capital Management LLC now owns 36,720 shares of the company's stock worth $528,000 after purchasing an additional 1,646 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Pharvaris by 2.0% in the 2nd quarter. Goldman Sachs Group Inc. now owns 56,951 shares of the company's stock worth $1,259,000 after purchasing an additional 1,115 shares during the last quarter. Eventide Asset Management LLC grew its position in Pharvaris by 23.6% in the 1st quarter. Eventide Asset Management LLC now owns 302,619 shares of the company's stock worth $5,659,000 after purchasing an additional 57,694 shares during the last quarter. Finally, Novo Holdings A S grew its position in Pharvaris by 23.2% in the 4th quarter. Novo Holdings A S now owns 516,321 shares of the company's stock worth $7,430,000 after purchasing an additional 97,378 shares during the last quarter. 70.21% of the stock is currently owned by institutional investors and hedge funds.
一些對衝基金和其他機構投資者最近買賣了該公司的股票。美國銀行DE在第一季度將其在Pharvaris的頭寸增加了1054.4%。美國銀行DE目前持有5,772股該公司股票,價值105,000美元,此前該公司在上一季度又購買了5,272股。Dafna Capital Management LLC在第四季度將其在Pharvaris的頭寸增加了4.7%。達夫納資本管理有限責任公司現在擁有36,720股該公司的股票,價值528,000美元,在上個季度又購買了1,646股。高盛股份有限公司在第二季度增加了其在Pharvaris的頭寸2.0%。高盛股份有限公司在上個季度增持了1,115股後,現在持有56,951股該公司股票,價值1,259,000美元。第一季度,Evende Asset Management LLC在Pharvaris的頭寸增加了23.6%。Evende Asset Management LLC在上個季度額外購買了57,694股後,現在擁有302,619股該公司股票,價值5,659,000美元。最後,Novo Holdings A S在第四季度增加了其在Pharvaris的頭寸23.2%。Novo Holdings A S現在持有該公司516,321股股票,價值7,43萬美元,上個季度又購買了97,378股。70.21%的股票目前由機構投資者和對衝基金持有。
Pharvaris Company Profile
Pharvaris公司簡介
(Get Rating)
(獲取評級)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).
Pharvaris N.V.是一家臨牀階段的生物製藥公司,專注於罕見疾病療法的開發和商業化。該公司開發了PHA121,這是一種小分子緩激肽B2受體拮抗劑,目前處於第二階段臨牀試驗,用於治療遺傳性血管性水腫(HAE)。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Pharvaris (PHVS)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- 免費獲取StockNews.com關於Pharvaris(PHV)的研究報告
- 這家醫療設備製造商準備好繼續反彈了嗎?
- 第三季度財報公佈前最值得關注的五(5)只股票
- Take-Two Interactive是否已經退化為一招小馬?
- 具有有趣內幕活動的四隻廉價股票
- 健康飲料製造商Celsius能否超越其Monster競爭對手?
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
接受Pharvaris Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Pharvaris和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧